Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Targets |
Polθ ( IC50 = 5.8 nM )
|
---|---|
ln Vitro |
RP-6685 is inert against ATPase activity and has an IC50 of 550 pM for pol activity against full-length Polθ [1]. With an IC50 of 0.94 μM, RP-6685 inhibits Polθ in HEK293 LIG4-/-cells[1].
|
ln Vivo |
In BRCA2-deficient HCT116 mice, RP-6685 (80 mg/kg; oral; BID for 21 days) showed strong anti-tumor effectiveness [1].
|
Animal Protocol |
Animal/Disease Models: Female CD1 nude mice (HCT116 BRCA2+/+ and BRCA2-/- xenograft tumor models)[1]
Doses: 80 mg/kg Route of Administration: po ; BID for 21 days Experimental Results: demonstrated tumor regression during the first 8 days of treatment in BRCA2-/- HCT116 model, while did not inhibit tumor growth in BRCA2+/+ HCT116 tumors mice. Animal/Disease Models: CD1 mice (20-30 g) [1] Doses: 2.5 mg/kg Route of Administration: iv or po; single dosage Experimental Results: CL (mL/min/kg) Vdss (L/kg) t1/2 (h) F (%) 36.8 1.1 0.4 66 |
References |
[1]. Bubenik M, et al. Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ. J Med Chem. 2022 Sep 20.
|
Molecular Formula |
C22H14F7N5O
|
---|---|
Molecular Weight |
497.37
|
Exact Mass |
497.11
|
Elemental Analysis |
C, 53.13; H, 2.84; F, 26.74; N, 14.08; O, 3.22
|
CAS # |
2832047-80-8
|
Appearance |
Powder
|
SMILES |
C1=CC(=CC=C1N(CC#CC2=NN=C(C=C2)N)C(=O)CC3=C(C=C(C=N3)C(F)(F)F)C(F)(F)F)F
|
InChi Key |
LHFFKHVGAKIDNO-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C22H14F7N5O/c23-14-3-6-16(7-4-14)34(9-1-2-15-5-8-19(30)33-32-15)20(35)11-18-17(22(27,28)29)10-13(12-31-18)21(24,25)26/h3-8,10,12H,9,11H2,(H2,30,33)
|
Chemical Name |
N-[3-(6-aminopyridazin-3-yl)prop-2-ynyl]-2-[3,5-bis(trifluoromethyl)pyridin-2-yl]-N-(4-fluorophenyl)acetamide
|
Synonyms |
RP6685; RP-6685; RP 6685
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~201.1 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0106 mL | 10.0529 mL | 20.1058 mL | |
5 mM | 0.4021 mL | 2.0106 mL | 4.0212 mL | |
10 mM | 0.2011 mL | 1.0053 mL | 2.0106 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.